Lakshmi (Prasad) Dasi
Contact
TEP 237Georgia TechBiography
Lakshmi Prasad Dasi, Ph.D. is a recognized researcher and entrepreneur in the field of cardiovascular innovation, with expertise spanning next-generation medical devices and AI-driven predictive modeling. He is Professor of Biomedical Engineering at the Georgia Institute of Technology and Emory University, where he holds the Rozelle Vanda Wesley Endowed Professorship.
Dr. Dasi is also the Founder of DASI Simulations, LLC, a startup successfully translating advanced computational technologies into clinical and commercial use. He has also founded YoungHeartValve Inc., which focuses on commercializing novel polymeric heart valves, a technology that began with an NIH R01 grant from his lab. His prior academic appointments include faculty positions at The Ohio State University and Colorado State University.
He is a Fellow of the American College of Cardiology (FACC) and a Fellow of the American Institute for Medical and Biological Engineering (FAIMBE), distinctions that reflect his contributions to advancing cardiovascular science and technology.
With a proven track record of moving innovations from academic laboratories into practical, real-world solutions, Dr. Dasi brings a unique perspective at the intersection of research, technology development, and commercialization.
Education
- Ph.D. in Civil and Environmental Engineering, 2004 - Georgia Institute of Technology
- M.S. in Civil and Environmental Engineering, 2000 - Georgia Institute of Technology
- B.Tech. in Civil Engineering, 1998 - Indian Institute of Technology Bombay
Research Interests
Dr. Lakshmi Prasad Dasi’s research integrates patient-specific computational modeling, biomechanics, and translational device innovation to improve outcomes in structural and congenital heart disease. His lab develops predictive simulation frameworks that leverage advanced imaging, machine learning, and reduced-order modeling to guide clinical decision-making and device design, with successful translation into FDA-cleared software used nationwide. Complementing these efforts, his group engineers bioinspired polymeric and bioresorbable heart valves, as well as next-generation LVAD technologies, to address durability, thrombosis, and pediatric needs. Across all projects, Dr. Dasi emphasizes rigorous validation, commercialization, and trainee-led discovery to advance precision cardiovascular therapies.
